Intellectual Product – Page 5

Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines

2 months ago talkbio0Tagged Clinical Data, COVID19 (disease), immune compromise, Invivyd, long-acting protection, Monoclonal Antibodies, Pemgarda, vaccine alternatives

Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data

Sen. Bill Cassidy Calls for Deferral of CDC Vaccine Meeting After RFK Jr. Panel Shakeup

2 months ago talkbio0Tagged ACIP, Advisory Committees, Bill Cassidy, Centers for Disease Control and Prevention (U.S.), Confirmation, Deferred, HELP Committee, Policy, RFK Jr., Senate, Vaccines

Bill Cassidy; RFK Jr.; CDC; vaccine advisory committee; ACIP; confirmation; deferral; Senate HELP Committee; vaccine policy

Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot

2 months ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, Long-acting injectable, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization, Yeztugo

Gilead; FDA approval; lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; long-acting injectable; WHO guidelines

Trump Administration Considers Limits on Direct-to-Consumer Drug Advertising

2 months ago talkbio0Tagged Ditiocarb, drug price, executive order, Health Policy, Pharma, pharmaceutical regulation, Transplant Registry Unified Management Program

Trump administration; DTC drug advertising; pharmaceutical regulation; drug pricing; executive order; health policy; pharma marketing

Genentech’s Kristin Bittenbender Named BIO Board Chair Amid Industry Challenges

2 months ago talkbio0Tagged Bio, biotech industry, Biotechnology, board chair, existential threats, genentech, Kristin Bittenbender, Leadership Change, Policy, United States Food and Drug Administration

BIO; Genentech; Kristin Bittenbender; board chair; biotech industry; FDA; existential threats; leadership change; biotechnology policy

Ousted ACIP Members Criticize RFK Jr.’s ‘Destabilizing’ Changes to U.S. Vaccine Policy

2 months ago talkbio0Tagged ACIP, CDC, Centers for Disease Control and Prevention (U.S.), Committee, Decision, Employment Termination, Policy, public health medicine (field), Recommendation, RFK Jr., Vaccines

ACIP; RFK Jr.; vaccine policy; CDC; committee dismissal; public health; vaccine recommendations; destabilizing decisions

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

2 months ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

FDA Launches New Priority Review Voucher Program Aligned with National Priorities

2 months ago talkbio0Tagged Accelerated, Biopharma, CNPV, Drug Approval, national priorities, Priority Review, public health medicine (field), Review [Publication Type], United States Food and Drug Administration, unmet

FDA; priority review voucher; CNPV; biopharma; drug approval; national priorities; accelerated review; unmet public health needs

Senate Drops Orphan Cures Act from Trump’s Tax Bill, Dealing Setback to Biopharma

2 months ago talkbio0Tagged Beak, Big Beautiful Bill, Biopharma, Drugs, Orphan, healthcare legislation, Infrequent, Ira (eukaryote), Mediation, Orphan Cures Act, Prices, reconciliation, Senate, Transplant Registry Unified Management Program

Orphan Cures Act; orphan drugs; Trump tax bill; biopharma; Senate; IRA price negotiations; rare diseases; Big Beautiful Bill; healthcare legislation; reconciliation bill

Shrinking Budgets and Rising Targets Pile Pressure on Pharma Marketers: Survey Highlights 2025 Challenges

2 months ago talkbio0Tagged Budgets, constraints, healthcare marketing trends, innovation, Pharma, Pressure- physical agent, Rising, shrinking budgets, Surveys, targets

pharma marketing; shrinking budgets; rising targets; 2025 survey; healthcare marketing trends; budget constraints; innovation; marketing pressure